TOP > 外国特許検索 > Purkinje cell-tropic viral vector

Purkinje cell-tropic viral vector

外国特許コード F110005412
整理番号 B116-01WO
掲載日 2011年9月5日
出願国 アメリカ合衆国
出願番号 22482707
公報番号 20100146649
公報番号 8912315
出願日 平成19年3月7日(2007.3.7)
公報発行日 平成22年6月10日(2010.6.10)
公報発行日 平成26年12月16日(2014.12.16)
国際出願番号 JP2007055017
国際公開番号 WO2007105744
国際出願日 平成19年3月7日(2007.3.7)
国際公開日 平成19年9月20日(2007.9.20)
優先権データ
  • 特願2006-062192 (2006.3.8) JP
  • 特願2006-198398 (2006.7.20) JP
  • 2007JP055017 (2007.3.7) WO
発明の名称 (英語) Purkinje cell-tropic viral vector
発明の概要(英語) The present invention relates to a Purkinje cell-tropic viral vector in which a modified L7 promoter and a therapeutic gene are operably linked to a virus-based plasmid vector.
特許請求の範囲(英語) [claim1]
1. A cerebellar Purkinje cell-tropic vector comprising a L7 promoter operably linked to a foreign gene operably linked to a virus-based plasmid vector, wherein the L7 promoter is selected from the group consisting of: a) a DNA consisting of the nucleotide sequence shown in SEQ ID NO:3,
b) a DNA consisting of the nucleotide sequence shown in SEQ ID NO:4, and
c) a DNA consisting of a nucleotide sequence fragment of SEQ ID NO:3 that contains at least the nucleotide sequence of 317 to 1322 of SEQ ID NO: 1.
[claim2]
2. The vector according to claim 1, wherein the virus is selected from an adenovirus, an adeno-associated virus, a retrovirus, a herpesvirus, a Sendai virus, and a lentivirus.
[claim3]
3. The vector according to claim 1, wherein the virus is a lentivirus.
[claim4]
4. The vector according to claim 1, wherein the vector is produced in a culture medium comprising a protease inhibitor to inhibit degradation of a viral protein.
[claim5]
5. The vector according to claim 4, wherein the viral protein is a glycoprotein present on the viral envelope.
[claim6]
6. The vector according to claim 4, wherein the protease inhibitor has a cathepsin K inhibitory activity.
[claim7]
7. The vector according to claim 1, wherein the vector is produced in a culture medium at pH 7.2 to pH 8.0.
[claim8]
8. The vector according to claim 1, wherein the vector is produced in a serum-free culture medium.
[claim9]
9. The vector according to claim 1, wherein the foreign gene is a therapeutic gene for Purkinje cell-affecting disease or a disease gene for the disease.
[claim10]
10. The vector according to claim 9, wherein the therapeutic gene is any one or more selected from genes encoding molecular chaperones including GTPase CRAG, ubiquitin chain assembly factor E4B (UFD2a), ATPase VCP/p97, HDJ-2, HSDJ, and BiP, apoptosis suppressors including YAPdeltaC, endoplasmic reticulum protein degradation-promoting molecules including ER degradation enhancing alpha-mannosidase-like protein (EDEM), ER sensor molecules including CREB/ATF family members OASIS, IRE1, PERK, and ATF6, sphingomyelinase, AT-mutated (atm), Reelin, Bcl-2, neprilysin, BDNF, and NGF, or siRNA(s) for any one or more selected from genes encoding ataxin-1, ataxin-2, ataxin-3, voltage-dependent calcium channel ala subunit, and PKCgamma .
[claim11]
11. The vector according to claim 9, wherein the disease gene is any one or more selected from genes with an abnormally expanded CAG repeat that encode ataxin-1, ataxin-2, ataxin-3, huntingtin, and voltage-dependent calcium channel alpha 1a subunit, and a gene encoding PKCgamma having a mutation.
[claim12]
12. A pharmaceutical composition for the treatment of cerebellar Purkinje cell-affecting disease comprising a vector according to claim 1, wherein the vector comprises the modified L7 promoter operably linked to a therapeutic gene for Purkinje cell-affecting disease.
[claim13]
13. The pharmaceutical composition according to claim 12, wherein the cerebellar Purkinje cell-affecting disease is any one selected from polyglutamine disease including spinocerebellar ataxia and Huntington disease, Niemann-Pick disease, ataxia-telangiectasia, autism, Alzheimer's disease, fetal alcohol syndrome, alcoholism, and age-related cerebellar ataxia.
[claim14]
14. A non-human mammal comprising a vector according to claim 1 introduced thereinto.
[claim15]
15. The non-human mammal according to claim 14, wherein the vector comprises the modified L7 promoter operably linked to one or more genes selected from the group consisting of genes with an abnormally expanded CAG repeat that encode ataxin-1, ataxin-2, ataxin-3, huntingtin, and voltage-dependent calcium channel ala subunit, and a gene encoding PKCgamma having a mutation.
[claim16]
16. A method for preparing a cerebellar Purkinje cell-tropic virus, the method comprising: i) introducing the cerebellar Purkinje cell-tropic vector of claim 1 into a host cell;
ii) culturing the host cell of (i) in a culture medium comprising a protease inhibitor; and
iii) isolating the cerebellar Purkinje cell-tropic virus from the culture medium.
[claim17]
17. The method according to claim 16, wherein the protease inhibitor has a cathepsin K inhibitory activity.
[claim18]
18. The method according to claim 16 or 17, wherein the culture medium has pH 7.2 to pH 8.0.
[claim19]
19. The method according to claim 16 or 17, wherein the culture medium is serum-free.
  • 発明者/出願人(英語)
  • HIRAI HIROKAZU
  • TORASHIMA TAKASHI
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
国際特許分類(IPC)
米国特許分類/主・副
  • 536/24.1
  • 424/93.1
  • 424/93.2
  • 424/93.6
  • 435/320.1
参考情報 (研究プロジェクト等) SORST Selected in Fiscal 2005
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close